Symphogen A/S (Lyngby, Denmark) was acquired by Servier in April 2020. 

Symphogen is a subsidiary of Servier and antibody center of excellence primarily focused on oncology and immune-oncology. The company has a highly efficient antibody discovery and research platform supported by comprehensive early development capabilities. 

The company’s antibody platform delivers antibodies with unique functionalities providing best or first in class potential as combination or mono therapy. The approach and capabilities are well suited for combination therapies at the core of future cancer treatment.

For more information, please contact:

Søren Lemonius, Msc

Managing General Partner

Phone: +45 4081 4889